Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2

Archives of Ophthalmology

Volumn 127, Issue 7, 2009, Pages 882-887

  Goyal, Sunali ^a,b   Chauhan, Sunil K ^a,b   Zhang, Qiang ^a,b   Dana, Reza ^a,b,c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; FLUORESCEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CELL INFILTRATION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; CYTOKINE PRODUCTION; DRY EYE; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA FLUORESCEIN ANGIOGRAPHY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD3; CONJUNCTIVA; CORNEA; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MONOCYTES; RECEPTORS, CCR2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650463091     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.125     Document Type: Article

References (34)

1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318-326.
2. Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124(6):723-728.
3. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2(2):124-130.
4. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584-589.
5. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338(7):436-445.
6. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2(2):108-115.
7. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126(2):219-225.
8. Lagu B, Gerchak C, Pan M, et al. Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. Bioorg Med Chem Lett. 2007;17(15):4382-4386.
9. Tylaska LA, Boring L, Weng W, et al. CCR2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine. 2002;18(4):184-190.
10. Oshima T, Sonoda KH, Tsutsumi-Miyahara C, et al. Analysis of corneal inflammation induced by cauterisation in CCR2 and MCP-1 knockout mice. Br J Ophthalmol. 2006;90(2):218-222.
11. Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46(8):2766-2771.
12. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221-232.
13. 1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126(12):1695-1699.
14. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003;121(8):1132-1140.
15. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006; 176(7):3950-3957.
16. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43 (8):2609-2614.
17. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19(3):201-211.
18. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292.
19. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996;2(11):1174-1178.
20. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol. 1994;55:97-179.
21. Charo IF. CCR2: from cloning to the creation of knockout mice. Chem Immunol. 1999;72:30-41.
22. Izikson L, Klein RS, Luster AD, Weiner HL. Targeting monocyte recruitment in CNS autoimmune disease. Clin Immunol. 2002;103(2):125-131.
23. Yamagami H, Yamagami S, Inoki T, Amano S, Miyata K. The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci. 2003;44(2):514-520.
24. Yamagami S, Yokoo S, Mimura T, Amano S. Effects of TGF-β2 on immune response-related gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci. 2004;45(2):515-521.
25. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137 (2):337-342.
26. Jones DT, Monroy D, Ji Z, Pflugfelder SC. Alterations of ocular surface gene expression in Sjögren's syndrome. Adv Exp Med Biol. 1998;438:533-536.
27. Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation. 1997;63(10):1501-1507.
28. Brito BE, O'Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci. 1999;40(11):2583-2589.
29. Rosenbaum JT, Planck ST, Huang XN, Rich L, Ansel JC. Detection of mRNA for the cytokines, interleukin-1 alpha and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci. 1995;36(10): 2151-2155.
30. McLeish W, Rubsamen P, Atherton SS, Streilein JW. Immunobiology of Langerhans cells on the ocular surface, II: role of central corneal Langerhans cells in stromal keratitis following experimental HSV-1 infection in mice. Reg Immunol. 1989;2(4):236-243.
31. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol. 2000;18:451-494.
32. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187(1):129-134.
33. Charbonnier AS, Kohrgruber N, Kriehuber E, Stingl G, Rot A, Maurer D. Macrophage inflammatory protein 3α is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med. 1999;190(12):1755-1768.
34. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250(2): 91-104.